bge
background
electrolyt
ce
capillari
electrophoresi
chikv
chikungunya
viru
dapi
eeev
eastern
equin
enceph
viru
elisa
immunosorb
assay
gidp
guanosin
triphosph
gt
guanyl
gtase
guanylyltransferas
laser
flight
spectromet
mtase
methyltransferas
nonstructur
protein
nw
new
world
ow
old
world
pfu
unit
pva
alcohol
quantit
revers
transcript
polymeras
chain
reaction
sah
homocystein
sam
methionin
veev
venezuelan
equin
enceph
viru
emerg
viral
pathogen
includ
alphavirus
chikungunya
chikv
venezuelan
equin
enceph
viru
veev
repres
signific
health
threat
human
popul
worldwid
alphavirus
classifi
base
geograph
distribut
new
world
nw
old
world
ow
alphavirus
ow
alphavirus
gener
arthrogen
includ
chikv
sindbi
viru
nw
alphavirus
veev
eastern
equin
enceph
viru
eeev
western
equin
enceph
viru
character
encephalitogen
phenotyp
alphavirus
replic
high
titer
cell
line
mosquito
vertebr
origin
possess
capabl
storag
lyophil
form
potenti
spread
aerosol
form
make
potenti
bioweapon
thu
virus
recogn
categori
b
prioriti
pathogen
us
govern
veev
caus
major
epidem
sever
part
world
involv
larg
number
equid
human
chikv
document
caus
diseas
sinc
explos
outbreak
la
island
involv
overwhelm
number
report
case
sinc
caus
recurr
outbreak
asia
part
world
lack
effect
safe
antivir
agent
alphavirus
includ
chikv
veev
make
pursuit
compound
antivir
activ
virus
highli
imper
alphavirus
individu
nonstructur
protein
nsp
produc
process
nonstructur
polyprotein
play
indispens
role
alphavir
life
cycl
cap
viral
genom
vital
step
alphavir
life
cycl
cap
structur
play
numer
biolog
role
includ
protect
mrna
cellular
exonucleas
effici
recognit
rna
eukaryot
translat
initi
factor
initi
translat
addit
cap
structur
also
prevent
recognit
member
host
innat
immun
pathway
andor
alphavirus
use
complet
distinct
molecular
mechan
cap
viral
mrna
host
cell
cellular
cap
enzym
typic
methyl
gtp
transfer
end
rna
contrast
alphavir
cap
enzym
nonstructur
protein
cap
viral
rna
two
major
step
first
methyl
gtp
transfer
methyl
group
methionin
sam
act
methyl
donor
gtp
methyl
moieti
get
coval
attach
enzym
transient
guanyl
gt
step
homocystein
sah
gener
coproduct
methyltransferas
mtase
step
cap
reaction
anoth
replic
protein
alphaviru
harbor
rna
triphosphatas
activ
contribut
cap
reaction
alphavirus
cleav
bond
specif
end
nascent
rna
prior
transfer
nascent
viral
rna
guanylyltransferas
gtase
step
mutat
analys
protein
revers
genet
studi
involv
live
viru
show
abrog
alphavir
activ
detriment
viral
growth
prove
cap
activ
essenti
step
viral
replic
virus
within
alphaviru
superfamili
shown
replic
membran
invagin
spherul
host
cell
also
vital
compon
replic
complex
anchor
ensembl
nsp
replic
factor
membran
primarili
amphipath
helix
secondarili
palmitoyl
site
protein
structur
alphaviru
member
alphaviru
genu
remain
elus
absenc
structur
develop
enzymat
assay
screen
develop
potent
inhibitor
target
replic
protein
requir
provid
platform
identif
character
inhibitor
viral
enzym
treat
diseas
caus
alphavir
infect
late
surg
develop
novel
assay
enzymat
activ
accentu
pursuit
novel
antivir
compound
previou
effort
develop
assay
biochem
character
inhibit
assay
focuss
gt
step
enzymat
reaction
approach
inhibit
studi
use
fluoresc
label
gtp
detect
western
blotelisa
use
monoclon
antibodi
quantif
enzymat
activ
assay
target
gt
activ
inhibit
util
expens
antibodi
suscept
identif
fals
positivesfals
neg
fluoresc
polar
fp
assay
also
develop
use
screen
small
molecul
chikv
assay
base
monitor
displac
fluoresc
label
gtp
analog
inhibitori
molecul
screen
potenti
assay
restrict
compound
compet
site
enzym
nucleosidesnucleosid
analog
repres
major
class
antivir
drug
nucleosid
analog
shown
display
antivir
activ
sever
medic
import
virus
includ
hiv
hepat
b
viru
herpesviru
sinefungin
samnucleosid
analog
shown
inhibit
viral
mtase
activ
consequ
abrog
viral
replic
vitro
member
flaviviru
famili
includ
zika
viru
west
nile
viru
dengu
viru
regard
alphavirus
antivir
agent
ribavirin
favipiravir
shown
vitro
activ
respect
addit
cytosin
analog
show
moder
vivo
efficaci
veev
recent
modifi
nucleosid
analog
previous
shown
effect
hepat
c
viru
human
coronaviru
found
inhibit
chikv
veev
replic
cell
cultur
suggest
employ
nucleosid
analog
alphavir
allevi
reward
approach
studi
nonradioact
capillari
electrophoresi
ce
assay
develop
measur
mtase
activ
alphavir
cap
enzym
independ
gt
activ
achiev
veev
truncat
construct
chikv
clone
recombinantli
express
purifi
use
assay
influenc
variou
reaction
paramet
methyl
reaction
veev
chikv
enzym
determin
mutant
veev
design
use
examin
format
alphavir
cap
reaction
use
differ
ce
method
addit
assay
use
character
known
inhibitor
alphaviru
sinefungin
aurintricarboxyl
acid
ata
use
assay
possibl
use
adenosin
analog
modul
mtase
activ
investig
one
compound
found
inhibit
mtase
activ
veev
chikv
adenosin
analog
inhibitor
identifi
use
assay
also
valid
inhibit
use
orthogon
nonradioact
immunosorb
assay
elisa
assay
antivir
efficaci
identifi
inhibitor
evalu
vitro
use
assay
intriguingli
compound
show
signific
inhibit
chikv
cell
studi
assert
reliabl
develop
assay
novel
mtase
assay
new
approach
use
adenosin
analog
target
alphaviru
may
promot
identif
novel
therapeut
alphavirus
vero
cell
procur
nation
centr
cell
scienc
ncc
pune
india
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
inactiv
fb
gibco
thermo
fisher
scientif
waltham
usa
recent
clinic
isol
chikv
strain
genbank
propag
vero
cell
use
standard
viral
adsorpt
techniqu
quantifi
standard
plaqu
assay
store
sam
sah
gtp
ump
caffein
sinefungin
ata
purchas
sigma
st
loui
mo
usa
cayman
chemic
ann
arbor
mi
usa
dissolv
dimethyl
sulfoxid
dmso
also
product
cayman
chemic
suppli
ethanol
clone
veev
amino
acid
residu
dna
contain
veev
gene
kind
gift
richard
j
kuhn
purdu
univers
usa
taken
templat
pcr
amplif
pcr
amplif
done
primer
pair
sens
antisens
gcat
veev
gene
ligat
tag
plasmid
posit
clone
subsequ
transform
express
host
rosetta
cultur
grown
overnight
terrif
broth
supplement
kanamycin
chloramphenicol
use
inoculum
ml
secondari
cultur
secondari
cultur
grown
till
reach
shift
cultur
induc
mm
isopropyl
iptg
allow
grow
anoth
h
cell
harvest
incub
centrifug
analyz
use
sdspage
mtasegt
mutant
gener
use
method
mutagenesi
use
specif
primer
chikv
amino
acid
residu
clone
purifi
describ
previous
cell
pellet
harvest
bacteri
cultur
resuspend
ml
bind
buffer
mm
tri
buffer
ph
mm
imidazol
mm
kcl
mm
phenylmethylsulfonyl
fluorid
pmsf
halt
proteas
inhibitor
thermo
fisher
scientif
dnase
promega
madison
wi
usa
ad
resuspend
cell
pellet
cell
pellet
incub
min
lyse
use
french
press
system
constant
system
ltd
daventri
uk
cell
lysat
centrifug
separ
insolubl
cellular
debri
solubl
fraction
contain
recombin
protein
clarifi
supernat
load
onto
acid
bead
qiagen
germantown
md
usa
graviti
flow
column
incub
min
collect
column
wash
buffer
contain
increas
concentr
imidazol
recombin
protein
elut
mm
imidazol
mm
tri
buffer
ph
mm
kcl
differ
fraction
analyz
use
sdspage
ident
protein
check
laser
flight
spectromet
digest
trypsin
fraction
contain
recombin
protein
mix
dialyz
dialysi
buffer
mm
tri
buffer
ph
mm
kcl
mm
dtt
mm
veev
mutant
express
purifi
affin
chromatographi
similar
express
purif
wt
protein
dialyz
protein
frozen
liquid
nitrogen
store
protein
thaw
need
concentr
requir
concentr
amicon
centrifug
filter
millipor
burlington
usa
product
mtase
reaction
sah
studi
two
distinct
method
detect
sah
detect
develop
detect
sah
perform
capillari
alcohol
pva
capillari
use
detect
ce
analysi
done
use
agil
ce
system
agil
technolog
santa
clara
ca
usa
fit
detector
dad
detect
system
electrophoret
separ
sam
sah
done
use
extend
light
path
capillari
cm
cm
effect
length
intern
diamet
sampl
inject
hydrodynam
appli
pressur
mbar
use
autosampl
follow
applic
kv
voltag
separ
analyt
capillari
thermost
sampl
vial
store
sampl
tray
detect
done
dad
coupl
uv
detect
system
cathod
end
capillari
wavelength
nm
begin
day
capillari
condit
use
follow
sequenc
rins
water
rins
naoh
rins
water
rins
run
buffer
two
run
capillari
rins
run
buffer
end
day
capillari
flush
min
water
subsequ
min
taken
instrument
examin
format
mutant
capillari
agil
technolog
cm
cm
effect
length
intern
diamet
employ
coat
capillari
suppress
flow
drastic
revers
voltag
polar
appli
across
end
coat
capillari
facilit
rapid
migrat
neg
charg
speci
gtp
capillari
thermost
sampl
vial
store
sampl
tray
achiev
baselin
separ
product
voltag
kv
appli
sampl
analyz
introduc
hydrodynam
capillari
use
mbar
pressur
use
autosampl
pva
capillari
flush
water
buffer
prior
first
run
day
two
success
run
capillari
rins
run
buffer
nm
wavelength
use
detect
quantif
analyt
mtase
reaction
carri
final
reaction
volum
mm
tri
buffer
ph
mm
dtt
mm
kcl
mm
gtp
gidp
guanosin
triphosph
mm
sam
veev
chikv
incub
detect
use
mutant
veev
mtase
reaction
except
increas
concentr
sam
mm
use
reaction
owe
higher
detect
limit
mtase
reaction
also
done
mutant
veev
use
neg
control
follow
studi
reaction
stop
differ
time
point
ad
acetonitril
volvol
ratio
mixtur
protein
precipit
min
g
supernat
transfer
sampl
vial
ce
analysi
reaction
done
duplic
compound
dissolv
dmso
dissolv
ethanol
typic
inhibit
assay
reaction
carri
reaction
volum
mm
tri
buffer
ph
mm
dtt
mm
kcl
mm
gtp
gidp
mm
sam
veev
chikv
sinefungin
ata
test
differ
concentr
around
report
inhibitori
concentr
valu
veev
reaction
mixtur
incub
h
test
concentr
control
reaction
mixtur
incub
along
inhibit
assay
contain
correspond
vehicl
concentr
compound
test
duplic
gt
reaction
perform
mm
tri
buffer
ph
mm
dtt
mm
nacl
mm
mm
dtt
gtp
sam
protein
min
detect
chikv
gt
activ
done
elisa
assay
report
earlier
briefli
reaction
mixtur
transfer
high
bind
elisa
plate
greiner
austria
reaction
stop
addit
equal
volum
sd
mm
edta
follow
incub
h
well
wash
twice
tbst
buffer
mm
tri
ph
mm
nacl
block
skim
milk
tbst
h
wash
incub
h
cap
monoclon
antibodi
merck
millipor
burlington
usa
subsequ
secondari
antibodi
affymetrix
ebiosci
san
diego
ca
usa
ad
well
incub
h
wash
tbst
final
detect
immunoreact
protein
substrat
genei
ad
well
plate
incub
reaction
stop
addit
equal
volum
n
color
develop
absorb
read
nm
obtain
use
plate
reader
cytat
biotek
instrument
inc
winooski
vt
usa
inhibitor
ad
reaction
mixtur
subject
elisa
procedur
describ
well
contain
reaction
mixtur
vehicl
control
use
posit
control
well
without
protein
taken
background
control
concentr
test
duplic
standard
curv
sah
obtain
plot
correct
peak
area
sah
concentr
peak
integr
data
acquisit
done
use
agil
ce
open
lab
analysi
softwar
associ
instrument
correct
peak
area
sah
taken
subtract
peak
area
obtain
blank
assay
contain
compon
reaction
mixtur
except
enzym
progress
reaction
quantifi
increas
area
peak
correspond
sah
intern
standard
use
compens
variabl
aris
due
differ
inject
volum
also
take
care
minor
fluctuat
migrat
time
differ
ce
run
intern
standard
improv
precis
quantif
analyt
act
standard
correct
migrat
time
caffein
use
intern
standard
assess
product
format
normal
valu
peak
area
sah
peak
area
caffein
ump
use
normal
peak
area
data
valu
normal
peak
area
intern
standard
run
averag
two
duplic
read
standard
deviat
calcul
use
microsoft
excel
percentag
inhibit
calcul
use
follow
equat
inhibit
x
correct
peak
area
product
presenc
inhibitor
blank
peak
area
substrat
present
reaction
mixtur
valu
sinefungin
ata
calcul
use
graphpad
prism
softwar
graphpad
san
diego
ca
usa
nonlinear
regress
use
curv
fit
equat
sigmoid
dose
respons
variabl
slope
use
interpol
valu
determin
valu
cytotox
determin
vero
cell
prior
evalu
antivir
efficaci
standard
mtt
bromid
assay
use
assess
cell
viabil
profil
vero
cell
briefli
vero
cell
seed
plate
incub
overnight
attach
next
day
cell
treat
differ
concentr
along
ethanol
posit
control
cell
incub
h
prior
addit
mtt
plate
incub
h
follow
addit
dmso
dissolv
result
formazan
crystal
final
absorb
measur
nm
use
cytat
plate
reader
biotek
instrument
inc
concentr
test
triplic
evalu
antivir
efficaci
compound
vitro
assay
perform
quantifi
chang
viral
titer
presenc
compound
vero
cell
seed
plate
incub
overnight
attach
cell
confluent
infect
chikv
moi
along
vari
concentr
compound
dmem
medium
fb
h
supernat
cell
harvest
store
cytopath
effect
cpe
observ
light
microscop
carl
zeiss
oberkochen
germani
hpi
hour
postinfect
studi
cell
pretreat
h
infect
compound
cell
monolay
wash
pb
viral
infect
done
moi
posttreat
simultan
treatment
cell
ad
media
h
postinfect
cell
cultur
supernat
harvest
h
infect
determin
viral
titer
titer
determin
perform
convent
assay
briefli
dilut
differ
viral
stock
prepar
dmem
medium
fb
use
infect
cell
monolay
h
infect
cell
wash
overlaid
carboxymethyl
cellulos
cmc
sigma
minimum
essenti
medium
mem
fb
incub
h
overlay
media
remov
cell
fix
stain
crystal
violet
solut
count
plaqu
viru
titer
indic
unit
per
millilit
pfu
per
ml
concentr
test
triplic
concentr
compound
abl
reduc
viral
titer
compar
vehicl
control
calcul
graphpad
prism
graphpad
softwar
monolay
vero
cell
incub
presenc
differ
concentr
h
prior
process
indirect
immunofluoresc
assay
monolay
cell
fix
min
follow
wash
dpb
cell
subject
triton
min
facilit
permeabil
wash
dpb
cell
incub
h
mous
monoclon
antibodi
recogn
alphaviru
group
surfac
antigen
santa
cruz
biotechnolog
inc
dalla
tx
usa
subsequ
wash
time
dpb
incub
anoth
h
goat
secondari
antibodi
conjug
fluorescein
isothiocyan
fitc
sigma
cell
nuclei
counterstain
dapi
imag
acquisit
done
evo
fl
imag
system
thermo
fisher
scientif
use
dapi
gfp
channel
imag
process
evo
fl
softwar
waltham
usa
quantifi
intracellular
viral
rna
cell
treat
compound
describ
section
cell
lyse
rna
extract
use
trizol
describ
manufactur
instruct
subsequ
cdna
gener
use
revers
transcriptas
promega
random
hexam
rna
recommend
manufactur
dna
use
amplifi
actin
viral
gene
employ
kapa
sybr
fast
univers
qpcr
kit
quantstudio
pcr
system
appli
biosystem
carlsbad
ca
usa
follow
manufactur
protocol
primer
sequenc
use
follow
forward
revers
actin
forward
actin
revers
idt
usa
melt
curv
analysi
perform
ascertain
specif
product
method
use
rel
quantif
actin
experi
undertaken
triplic
veev
gene
clone
e
coli
fuse
tag
n
terminu
construct
confirm
sanger
sequenc
recombin
protein
purifi
homogen
use
affin
chromatographi
two
mutant
veev
gener
mutagenesi
recombin
protein
purifi
use
protocol
enzymat
character
fig
purifi
protein
sampl
analyz
sdspage
gel
homogen
fig
ident
purifi
veev
wt
protein
confirm
trypsin
digest
data
shown
truncat
form
chikv
residu
recent
character
laboratori
also
purifi
mtase
enzymat
activ
purifi
protein
veev
chikv
character
use
develop
nonradioact
method
run
buffer
background
electrolyt
bge
optim
achiev
good
separ
analyt
perform
mtase
assay
main
purpos
resolv
sam
sah
peak
sam
substrat
sah
one
product
mtase
reaction
initi
trial
resolv
analyt
mm
phosphat
buffer
ph
mm
glycylglycin
buffer
ph
mm
tri
buffer
ph
mm
phosphat
buffer
ph
tri
use
mm
borat
buffer
ph
bge
ce
run
buffer
borat
suffer
either
poor
baselin
separ
peak
broaden
current
leakag
run
complet
separ
sam
sah
achiev
use
borat
buffer
addit
two
diastereomer
form
sam
r
distinguish
ce
analysi
fig
furthermor
inject
paramet
name
inject
mode
electrokinet
hydrodynam
inject
pressur
time
run
voltag
optim
hydrodynam
pressur
inject
mbar
pressur
kv
run
voltag
normal
polar
ce
run
use
borat
buffer
alon
abl
achiev
complet
baselin
separ
sam
sah
suffer
poor
migrat
time
reproduc
addit
organ
modifi
acetonitril
addit
bge
enhanc
resolut
migrat
time
reproduc
peak
methanol
also
test
organ
modifi
could
improv
reproduc
migrat
time
percentag
acetonitril
separ
buffer
optim
strike
balanc
migrat
time
resolut
substrat
gtp
could
detect
within
min
ce
run
time
given
ce
run
condit
fig
reaction
buffer
inject
without
deprotein
reaction
mixtur
protein
compon
adher
capillari
wall
affect
migrat
time
subsequ
run
use
trichloroacet
acid
deprotein
reaction
mixtur
result
peak
deform
essenti
due
chang
matrix
compon
low
ph
therefor
acetonitril
vv
use
precipit
protein
inject
analysi
ce
acetonitril
sampl
buffer
give
rise
transient
salt
act
lead
ion
acetonitril
function
termin
ion
provid
high
field
strength
sampl
concentr
band
sharpen
improv
overal
separ
effici
analysi
condit
could
detect
sah
concentr
low
use
extend
light
path
capillari
also
optim
bge
separ
paramet
ce
analysi
product
mtase
reaction
veev
mutant
use
capillari
evalu
effici
variou
concentr
me
buffer
ph
separ
reaction
compon
mtase
assay
reaction
mixtur
could
identifi
reaction
mixtur
use
mm
me
buffer
bge
use
inject
run
paramet
mention
methodolog
section
mm
me
buffer
offer
baselin
separ
product
proteic
materi
remain
gtp
gdp
present
reaction
mixtur
two
ce
method
valid
sah
detect
optim
ce
analysi
condit
respect
limit
quantit
rsd
migrat
time
linear
tabl
calibr
curv
analyt
sah
gener
use
differ
concentr
analyt
use
intern
standard
linear
calibr
curv
correct
migrat
time
sah
found
detect
use
capillari
correct
migrat
time
calcul
preliminari
character
mtase
reaction
use
method
veev
truncat
chikv
incub
differ
concentr
reaction
mixtur
differ
time
period
enzym
activ
veev
min
chikv
could
detect
min
use
sam
methyl
acceptor
gtp
includ
reaction
satur
concentr
mm
lower
concentr
enzymessubstr
yield
detect
product
within
assay
time
concentr
enzym
substrat
use
subsequ
experi
next
mtase
activ
veev
chikv
assay
determin
optim
reaction
paramet
viz
ph
magnesium
ion
concentr
temperatur
salt
kcl
concentr
analysi
temperatur
depend
alphaviru
mtase
activ
demonstr
profil
temperatur
depend
activ
maximum
activ
fig
next
determin
ph
maxim
mtase
activ
veev
chikv
activ
perform
ph
rang
enzym
show
ph
maxim
correspond
physiolog
ph
fig
thu
mtase
reaction
favour
physiolog
condit
mimic
cellular
environ
insid
host
cell
viral
rna
cap
take
place
chikv
increas
concentr
kcl
final
assay
buffer
mm
neglig
effect
mtase
activ
mm
kcl
steep
reduct
enzymat
activ
veev
chikv
fig
mtase
activ
veev
chikv
function
magnesium
concentr
evalu
use
ce
method
gradual
declin
enzymat
activ
increas
ion
concentr
observ
fig
observ
agreement
earlier
find
report
alphavir
enzym
requir
magnesium
ion
mtase
activ
taken
togeth
condit
employ
enzymat
assay
veev
chikv
exhibit
highest
enzymat
activ
ph
kcl
concentr
mm
absenc
magnesium
ion
experi
gtp
taken
methyl
acceptor
presenc
absenc
magnesium
ion
perform
optim
buffer
condit
intriguingli
observ
absenc
metal
ion
mtase
reaction
gtp
proce
linearli
h
sah
format
show
linear
rang
contrast
magnesium
ion
act
cofactor
subsequ
gt
reaction
present
progress
curv
becam
nonlinear
h
fig
specul
subsequ
gt
reaction
guanyl
might
affect
activ
enzym
product
inhibit
henc
decoupl
mtase
gt
reaction
catalyz
enzym
nonhydrolyz
analog
gtp
nonhydrolyz
bond
gidp
use
fig
use
gidp
exclud
possibl
guanyl
interfer
linear
sah
format
reaction
time
thu
subsequ
assay
develop
test
inhibitor
gidp
use
instead
gtp
methyl
acceptor
reaction
time
maintain
h
typic
electropherogram
mtase
reaction
assay
mixtur
differ
time
point
shown
figur
mutant
veev
taken
neg
control
increas
peak
area
correspond
sah
time
mtase
reaction
mixtur
observ
mutant
shown
defici
format
intermedi
coval
complex
gt
enzym
reaction
character
molecular
mechan
rna
cap
reaction
alphavir
format
mutant
protein
analyz
achiev
mutat
engin
veev
purifi
mutant
use
enzym
character
hypothes
otherwis
form
transient
cap
reaction
coval
attach
alphaviru
protein
moieti
could
observ
reaction
mixtur
mtase
reaction
carri
mutant
format
analyz
help
capillari
use
revers
voltag
polar
capillari
end
fig
reaction
sampl
also
spike
posit
identif
product
ump
taken
intern
standard
analysi
reaction
mutant
presenc
sam
gtp
show
linear
format
period
fig
peak
correspond
absent
sinefungin
ata
ad
mtase
reaction
mixtur
confirm
mutant
inde
produc
valid
establish
assay
sah
detect
inhibit
effici
two
known
inhibitor
sinefungin
ata
evalu
veev
chikv
respect
valu
enzym
calcul
fig
sinefungin
ata
known
inhibitor
veev
valu
sinefungin
ata
veev
chikv
shown
tabl
valu
sinefungin
ata
calcul
mtase
assay
similar
one
report
earlier
observ
slight
differ
valu
sinefungin
ata
veev
attribut
differenti
fold
protein
owe
differ
purif
protocol
differ
concentr
substrat
use
assay
valid
util
mtase
assay
screen
inhibitor
alphavir
mtase
inhibit
effici
two
inhibitor
evalu
mtase
activ
chikv
previous
use
develop
mtase
assay
adenosin
analog
evalu
potenc
inhibit
mtase
enzym
activ
veev
chikv
fix
concentr
inhibitor
candid
use
assess
inhibit
effici
among
compound
test
show
effect
inhibit
enzym
fig
indirect
elisa
assay
also
perform
measur
adduct
format
detect
coval
bound
protein
form
result
gt
activ
use
antibodi
assay
also
show
reduct
chikv
gt
activ
presenc
inhibitor
valu
confirm
chikv
gt
activ
inhibit
fig
effect
cell
viabil
examin
vero
cell
exert
weak
cytotox
effect
cell
concentr
h
fig
remov
possibl
mediat
cytotox
concentr
use
investig
antivir
activ
test
vitro
antivir
efficaci
cell
grown
presenc
vari
concentr
h
viral
titer
quantifi
use
assay
display
signific
inhibit
infecti
progeni
viru
fig
exhibit
inhibit
cpe
monitor
h
infect
fig
activ
confirm
chikv
immunostain
assay
antibodi
use
evalu
chikv
reduct
cell
cultur
presenc
fluoresc
bare
detect
infect
cell
treat
compound
compar
untreat
cell
confirm
reduct
chikv
antigen
express
treat
cell
fig
abil
inhibit
viral
rna
insid
infect
cell
assess
treatment
infect
cell
compound
led
reduct
intracellular
viral
rna
rel
cell
viral
rna
gradual
reduc
treat
cell
concentr
compound
approxim
reduct
observ
fig
complement
data
assay
taken
togeth
result
assay
immunofluoresc
indic
inhibit
chikv
replic
cell
cultur
identifi
stage
viral
replic
affect
ad
infect
cell
monolay
differ
time
point
fig
pretreat
cell
show
minim
inhibitori
effect
chikv
infect
addit
compound
hpi
hpi
show
mark
reduct
chikv
viral
titer
effici
ad
hpi
suggest
inhibit
earli
postentri
step
viral
replic
cycl
time
depend
antivir
effici
compound
agreement
activ
alphavirus
use
unconvent
mechan
rna
cap
distinct
host
counterpart
transfer
methyl
group
sam
gtp
occur
transguanyl
step
transfer
gtp
rna
alphaviru
cap
enzym
add
type
cap
structur
nascent
rna
rna
cap
critic
point
viral
life
cycl
promis
candid
develop
therapeut
intervent
alphavirus
mtase
activ
recombin
demonstr
differ
alphavirus
includ
sinv
veev
previou
effort
detect
mtase
activ
base
detect
radioact
product
albeit
sensit
reliabl
altern
cumbersom
radiolabel
also
caus
environment
health
cost
wast
regulatori
issu
anoth
drawback
use
techniqu
sah
produc
reaction
inhibit
activ
methyltransferas
mtase
recent
altern
radioact
assay
number
colorimetr
fluorometr
assay
develop
commerci
character
mtase
enzym
coupl
assay
wherein
sah
gener
mtase
reaction
subsequ
act
upon
enzym
includ
assay
mixtur
final
product
coupl
assay
quantifi
colorimetr
fluorometr
detect
approach
indirect
circumv
problem
sah
accumul
act
potent
inhibitor
mtase
enzym
assay
howev
use
inhibitor
screen
suffer
artefact
aris
mainli
promiscu
sever
compound
interfer
enzym
coupl
system
inhibit
inhibitor
identifi
screen
strategi
requir
secondari
assay
hit
valid
consid
studi
ce
method
develop
studi
hold
sever
advantag
simpl
sampl
prepar
low
sampl
requir
low
cost
also
elimin
need
expens
potenti
hazard
radioact
materi
moreov
assay
reli
direct
detect
sah
gener
mtase
reaction
therebi
minim
possibl
interfer
inhibitor
compound
report
assay
allow
rapid
detect
mtase
activ
cap
enzym
whole
ce
analysi
take
min
includ
buffer
run
two
run
multipl
sampl
analyz
autom
inject
procedur
without
manual
intervent
consecut
run
assay
use
batch
screen
inhibitor
modifi
adapt
fulli
autom
ce
assay
separ
reaction
mixtur
mutant
use
pva
capillari
demonstr
studi
alanin
substitut
posit
disrupt
format
phosphoramid
bond
support
hypothesi
alphavir
cap
enzym
methyl
gtp
hydrolyz
gmp
transfer
rna
unlik
host
cap
enzym
attract
drug
target
effect
perturb
feed
drug
discoveri
pipelin
therapeut
sequenc
align
reveal
put
mtase
domain
core
region
span
amino
acid
veev
highli
conserv
within
alphaviru
superfamili
cap
enzym
alphavirus
share
high
level
sequenc
homolog
thu
develop
inhibitor
warrant
therapeut
moreov
virus
superfamili
includ
sever
plant
anim
virus
bamboo
mosaic
viru
brome
mosaic
viru
tobacco
mosaic
viru
alfalfa
mosaic
viru
hepat
e
viru
carri
cap
viral
rna
use
mechan
similar
nonradioact
assay
provid
robust
versatil
platform
screen
identif
novel
inhibitor
viral
cap
enzym
similar
mtase
develop
assay
mtase
activ
base
gener
detect
method
sah
form
mtase
reaction
alphaviru
assay
condit
sah
accumul
mtase
reaction
linear
least
h
agreement
report
veev
sinv
detect
rang
use
character
inhibitor
test
compound
show
effici
inhibit
veev
chikv
taken
cell
viral
inhibit
studi
deriv
tubercidin
known
adenosin
kinas
inhibitor
shown
possess
antitumor
activ
antiseizur
activ
demonstr
vivo
compound
also
studi
potenti
therapeut
agent
treat
epilepsi
use
mice
model
role
cellular
kinas
alphaviru
replic
remain
poorli
understood
recent
studi
profil
cellular
kinom
follow
chikv
infect
found
number
kinas
undergo
chang
term
abund
activ
knowledg
adenosin
kinas
implic
chikv
infect
studi
thu
host
adenosin
kinas
seem
involv
alphaviru
infect
addit
studi
indic
affect
earli
postentri
replic
step
viral
life
cycl
though
extens
studi
requir
identifi
possibl
cellular
viral
target
stage
reason
believ
antivir
effect
like
least
partial
attribut
inhibit
alphavir
studi
also
need
screen
improv
inhibit
potenc
compound
similar
absenc
structur
rather
difficult
establish
relationship
sar
thu
point
time
abl
conjectur
interact
differ
moieti
compound
specif
amino
acid
residu
chemic
modif
addit
remov
chemic
moietymoieti
may
result
enhanc
potenc
term
increas
efficaci
improv
pharmacokinet
properti
avail
structur
alphaviru
genu
extens
studi
requir
use
refer
compound
ration
drug
design
identificationdevelop
potent
specif
therapeut
agent
target
protein
conclus
simpl
robust
versatil
assay
measur
mtase
activ
veev
chikv
develop
favor
assay
paramet
mtase
activ
veev
chikv
viz
ph
temperatur
salt
concentr
metal
ion
concentr
optim
mechanist
studi
format
mutant
analyz
help
pva
capillari
use
separ
ce
method
assay
use
evalu
valu
known
inhibitor
sinefungin
ata
evalu
enzymat
activ
presenc
potenti
inhibitor
led
identif
adenosin
analog
inhibitor
mtase
activ
enzym
potent
hit
compound
evalu
secondari
orthogon
elisa
assay
quantit
adduct
form
gt
activ
show
mark
reduct
chikv
replic
evid
result
plaqu
reduct
assay
cpe
reduct
ifa
studi
develop
assay
acceler
screen
inhibitor
alphavirus
identif
develop
new
antivir
drug
alphavirus
effect
inhibit
chikv
replic
cell
cultur
possibl
new
approach
target
alphavir
adenosin
analog
investig
identif
develop
antivir
agent
rm
sm
conduct
experi
analyz
data
rm
st
plan
experi
analyz
data
wrote
manuscript
